Immunogenicity and Protective Efficacy of BBV152, Whole Virion Inactivated SARS- CoV-2 Vaccine Candidates in the Syrian Hamster Model

Overview

Journal iScience

Publisher Cell Press

Date 2021 Feb 1

PMID 33521604

Citations 50

Authors

Sreelekshmy Mohandas

Pragya D Yadav

Anita Shete-Aich

Priya Abraham

Krishna Mohan Vadrevu

Gajanan Sapkal

Chandrashekhar Mote

Dimpal Nyayanit

Nivedita Gupta

Vellimedu Kannappa Srinivas

Manoj Kadam

Abhimanyu Kumar

Triparna Majumdar

Rajlaxmi Jain

Gururaj Deshpande

Savita Patil

Prasad Sarkale

Deepak Patil

Raches Ella

Sai D Prasad

Sharda Sharma

Krishna M Ella

Samiran Panda

Balram Bhargava

Affiliations

Soon will be listed here.

Abstract

The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.

Citing Articles

An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals.

Offersgaard A, Duarte Hernandez C, Zhou Y, Duan Z, Gammeltoft K, Hartmann K Sci Rep. 2024; 14(1):17039.

PMID: 39048693 PMC: 11269720. DOI: 10.1038/s41598-024-67570-0.

Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.

Handabile C, Ohno M, Sekiya T, Nomura N, Kawakita T, Kawahara M Sci Rep. 2024; 14(1):4204.

PMID: 38378856 PMC: 10879490. DOI: 10.1038/s41598-024-54421-1.

Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters.

Mohandas S, Shete A, Kumar A, Wakchaure K, Rai V, Mote C Front Microbiol. 2023; 14:1183763.

PMID: 37426033 PMC: 10325568. DOI: 10.3389/fmicb.2023.1183763.

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India.

Kakkar S, Jain E, Jain A, Dewan P Acta Haematol. 2023; 146(5):391-396.

PMID: 37331336 PMC: 11251649. DOI: 10.1159/000531448.

Molecular Characterization and Selection of Indigenous SARS-CoV-2 Delta Variant for the Development of the First Inactivated SARS-CoV-2 Vaccine of Pakistan.

Aziz M, Mukhtar N, Anjum A, Mushtaq M, Shahid M, Ali M Vaccines (Basel). 2023; 11(3).

PMID: 36992191 PMC: 10051781. DOI: 10.3390/vaccines11030607.

References

Phan L, Nguyen T, Luong Q, Nguyen T, Nguyen H, Le H . Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020; 382(9):872-874. PMC: 7121428. DOI: 10.1056/NEJMc2001272. View

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M . Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020; 369(6499):77-81. PMC: 7202686. DOI: 10.1126/science.abc1932. View

Sia S, Yan L, Chin A, Fung K, Choy K, Wong A . Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020; 583(7818):834-838. PMC: 7394720. DOI: 10.1038/s41586-020-2342-5. View

Rogers T, Zhao F, Huang D, Beutler N, Burns A, He W . Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020; 369(6506):956-963. PMC: 7299280. DOI: 10.1126/science.abc7520. View

Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann P, Nakajima N . Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020; 117(28):16587-16595. PMC: 7368255. DOI: 10.1073/pnas.2009799117. View

Lv Z, Deng Y, Ye Q, Cao L, Sun C, Fan C . Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020; 369(6510):1505-1509. PMC: 7402622. DOI: 10.1126/science.abc5881. View

Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W . Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020; 182(3):713-721.e9. PMC: 7275151. DOI: 10.1016/j.cell.2020.06.008. View

Krammer F . SARS-CoV-2 vaccines in development. Nature. 2020; 586(7830):516-527. DOI: 10.1038/s41586-020-2798-3. View

Islam M, Nasiruddin M, Khan I, Mishra S, Kudrat-E-Zahan M, Riaz T . A Perspective on Emerging Therapeutic Interventions for COVID-19. Front Public Health. 2020; 8:281. PMC: 7362761. DOI: 10.3389/fpubh.2020.00281. View

10.

Yu J, Tostanoski L, Peter L, Mercado N, McMahan K, Mahrokhian S . DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020; 369(6505):806-811. PMC: 7243363. DOI: 10.1126/science.abc6284. View

11.

Pandey S, Pande V, Sati D, Upreti S, Samant M . Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci. 2020; 256:117956. PMC: 7289747. DOI: 10.1016/j.lfs.2020.117956. View

12.

Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S . Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 2004; 79(1):503-11. PMC: 538722. DOI: 10.1128/JVI.79.1.503-511.2005. View

13.

Docea A, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M . A new threat from an old enemy: Re‑emergence of coronavirus (Review). Int J Mol Med. 2020; 45(6):1631-1643. PMC: 7169834. DOI: 10.3892/ijmm.2020.4555. View

14.

Clements J, Freytag L . Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses. Clin Vaccine Immunol. 2016; 23(6):438-441. PMC: 4895008. DOI: 10.1128/CVI.00214-16. View

15.

Luan J, Lu Y, Jin X, Zhang L . Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020; 526(1):165-169. PMC: 7102515. DOI: 10.1016/j.bbrc.2020.03.047. View

16.

Mohandas S, Jain R, Yadav P, Shete-Aich A, Sarkale P, Kadam M . Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection. Indian J Med Res. 2020; 151(5):479-482. PMC: 7530454. DOI: 10.4103/ijmr.IJMR_2235_20. View

17.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

18.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

19.

Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V . SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 2020; 146:111769. PMC: 7833750. DOI: 10.1016/j.fct.2020.111769. View

20.

Addetia A, Crawford K, Dingens A, Zhu H, Roychoudhury P, Huang M . Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020; 58(11). PMC: 7587101. DOI: 10.1128/JCM.02107-20. View